On May 17, 2018 SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS) reported that data from the Company’s ongoing Phase 1/2 study of galinpepimut-S (GPS) in combination with Bristol Myers Squibb’s nivolumab in patients with Wilms Tumor 1 + ovarian cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting being held June 1 – 5, 2018 in Chicago, Illinois (Press release, Sellas Life Sciences, MAY 17, 2018, View Source [SID1234526776]). Additionally, following the positive outcome in triple negative breast cancer patients (TNBC) from the Phase 2b trial for NeuVax, SELLAS will be conducting clinical and regulatory advisory board meetings at ASCO (Free ASCO Whitepaper) based on the independent Data Safety Monitoring Board recommendation to expeditiously seek regulatory guidance by the FDA for the development of NeuVax in TNBC.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Clinical and immunological data from the ongoing Phase 1/2 GPS plus nivolumab trial evaluating GPS in patients with recurrent WT1+ ovarian cancer in second or greater clinical remission after salvage chemotherapy will be presented. Details for the presentation are as follows:
Title: A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.
Presenter: Roisin E. O’Cearbhaill, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number: 5553
Poster Session: Gynecologic Cancer
Date and Time: June 4, 2018, 1:15PM – 4:45PM CT
Location: McCormick Place, Hall A